- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00070928
Valerian to Improve Sleep in Patients With Parkinson's Disease
Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease
Study Overview
Detailed Description
Patients with PD have exceptionally poor sleep. Sleep in patients with PD is characterized by excessive activity in surface electromyographic (EMG) recordings from many different muscle groups. Despite sleep disturbances, approximately 50% of patients experience a transient (1 to 3 hour) reduction in waking motor symptoms upon arising in the morning. This effect has been termed Sleep Benefit. This study will evaluate the effects of valerian, a medicinal herb, on the sleep of patients with PD.
This is a 17 day study where participants will be evaluated by polysomnography on days one, two, three, sixteen and seventeen.. Polysomnographic measurements will include customary variables such as total sleep time, sleep efficiency, and sleep latency, as well as EMG measures of periodic and isolated muscle activity during sleep. Participants will be required to keep a detailed sleep log of their self reported sleep characteristics across the entire 17 study nights. Outcomes will include measures of both nocturnal sleep and waking motor function. Assessments of motor function will be made the morning immediately following Nights 3 and 17 in order to test for improvement related to improved sleep. On the morning following Night 17, participants are provided with a one-week supply of valerian in an Open Label extension. Participants are provided an additional Sleep Log for this week and asked to return the Sleep Log when they complete the Open Label phase.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory University Medical School/Wesley Woods Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Idiopathic Parkinson's disease
- Willing to undergo overnight, in-lab polysomnography
- Sufficient literacy to allow completion of sleep logs
- Stable doses and timing of all Parkinsonian medications during the course of the trial
Exclusion Criteria
- Dementia
- Parkinsonism secondary to toxic, infectious, or other medical conditions
- History of stroke, cerebellar disease, or progressive supranuclear palsy
- History of liver or renal disease
- History of duodenal or bladder obstruction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Investigators
- Principal Investigator: Donald L. Bliwise, PhD, Emory University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01AT000611-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
Clinical Trials on valerian
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)CompletedSleep Initiation and Maintenance DisordersUnited States
-
China Medical University HospitalRecruiting
-
PiLeJeCompletedSleep Disorders Related to AnxietyFrance
-
University Hospital, BordeauxUniversity of BordeauxCompleted
-
Max Zeller Soehne AGUniversity of BaselCompletedCognitive Dysfunction | Sleep Disorders, Circadian RhythmSwitzerland
-
Federal University of the Valleys of Jequitinhonha...University of Campinas, BrazilCompletedBlood Pressure | Dental Anxiety | Heart RateBrazil
-
Pascoe Pharmazeutische Praeparate GmbHTerminatedDepressive DisorderGermany
-
Pascoe Pharmazeutische Praeparate GmbHCompletedHealthy | Sleep QualityGermany